- Home
- BELFB vs ORKA Comparison
BELFB vs ORKA Comparison
Compare BELFB & ORKA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BELFB
- ORKA
- Stock Information
- Founded
- BELFB 1949
- ORKA 2004
- Country
- BELFB United States
- ORKA United States
- Employees
- BELFB N/A
- ORKA N/A
- Industry
- BELFB
- ORKA Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- BELFB
- ORKA Health Care
- Exchange
- BELFB Nasdaq
- ORKA Nasdaq
- Market Cap
- BELFB 865.9M
- ORKA 354.2M
- IPO Year
- BELFB N/A
- ORKA N/A
- Fundamental
- Price
- BELFB $100.10
- ORKA $12.60
- Analyst Decision
- BELFB Strong Buy
- ORKA Strong Buy
- Analyst Count
- BELFB 4
- ORKA 8
- Target Price
- BELFB $100.75
- ORKA $39.71
- AVG Volume (30 Days)
- BELFB 182.5K
- ORKA 341.3K
- Earning Date
- BELFB 07-23-2025
- ORKA 08-15-2025
- Dividend Yield
- BELFB 0.28%
- ORKA N/A
- EPS Growth
- BELFB N/A
- ORKA N/A
- EPS
- BELFB 3.42
- ORKA N/A
- Revenue
- BELFB $558,940,000.00
- ORKA N/A
- Revenue This Year
- BELFB $18.21
- ORKA N/A
- Revenue Next Year
- BELFB $7.91
- ORKA N/A
- P/E Ratio
- BELFB $28.68
- ORKA N/A
- Revenue Growth
- BELFB N/A
- ORKA N/A
- 52 Week Low
- BELFB $58.00
- ORKA $5.49
- 52 Week High
- BELFB $100.52
- ORKA $52.32
- Technical
- Relative Strength Index (RSI)
- BELFB 76.80
- ORKA N/A
- Support Level
- BELFB $95.51
- ORKA N/A
- Resistance Level
- BELFB $98.55
- ORKA N/A
- Average True Range (ATR)
- BELFB 3.45
- ORKA 0.00
- MACD
- BELFB 0.73
- ORKA 0.00
- Stochastic Oscillator
- BELFB 97.50
- ORKA 0.00
About BELFB Bel Fuse Inc. Class B
Bel Fuse Inc designs and manufactures electronic components that protect and connect electronic circuits. Its product portfolio is divided into three categories: magnetic solutions, power solutions & protection, and connectivity solutions. These products are used for the computer, networking, telecommunications, transportation and defense/aerospace, automotive, medical, and consumer electronics industries. Its geographical segments are the United States, Macao, United Kingdom, Slovakia, Germany, Switzerland, and All other foreign countries. Majority of the revenue is derived from United States.
About ORKA Oruka Therapeutics Inc. Common Stock
Oruka Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing novel monoclonal antibody therapeutics for psoriasis (PsO) and other inflammatory and immunology (I&I) indications. Its lead program, ORKA-001, is designed to target the p19 subunit of interleukin-23 (IL-23p19) for the treatment of PsO. The company's co-lead program, ORKA-002, is designed to target interleukin-17A and interleukin-17F (IL-17A/F) for the treatment of PsO, psoriatic arthritis (PsA), and other conditions. These programs each bind their respective targets at high affinity and incorporate half-life extension technology to increase exposure and decreasing dosing frequency.